**Alpha Adrenergic Receptors: A Brief Perspective**

Dr. Sangavai Mathiazaghan\(^1\), Dr. S. Anand\(^2\), Dr. R. Parthiban\(^3\)

*Post Graduates, Department of Pharmacology, Sree Balaji Medical College and Hospital, Chromepet, Chennai.*

**Abstract:** In the last decade, knowledge of \(\alpha\)-adrenoceptors has expanded enormously. It is the purpose of this review to present the current status of our knowledge of alpha adrenergic receptor subtypes. The goal is to provide a brief perspective as a context for our current understanding and to highlight the gaps in our current understanding. From a pharmacological perspective, it should permit the development of very selective drugs with relatively few side effects.

**Key Words:** \(\alpha\)-adrenergic receptors, subtypes, locations, functions, agonists, antagonists.

### I. History

Historically, adrenergic receptors were divided into two major types, \(\alpha\)- and \(\beta\)-adrenergic receptors (1). The adrenotropic receptors are those hypothetical structures or systems located in, on or near the muscle or gland cells affected by epinephrine (2). The concept of a receptive mechanism was introduced by Langley (3, 4) to explain the action of curare on skeletal muscle. Dale was probably the first to make significant use of the receptor concept in connection with the sympathetic nervous system. In his classical paper (5) on the sympatholytic action of the ergot alkaloids, he recognized that what he called the sympathetic myoneural junction could also be called ‘the receptive mechanism for adrenaline’; and he used this mechanism to explain the fact that the ergot alkaloids prevented only the motor (excitatory) actions of epinephrine and had no effect on the inhibitory actions of epinephrine or on the excitatory actions of barium or pituitrin.

**Subtypes of Alpha Adrenergic Receptors**

The initial evidence for subtypes of \(\alpha\) 1-adrenergic receptors was obtained in studies of adrenergic receptor mediated contraction of various vascular smooth muscles (6, 7). Data from radioligand binding studies, on the other hand, have produced a consistent definition of \(\alpha\) adrenergic receptor subtypes, which has been confirmed by the molecular cloning of these receptors (8).

\(\alpha\)-adrenergic receptor

\[
\begin{align*}
\alpha-1, \alpha-2 \\
\alpha-1A & \quad \alpha-1B & \quad \alpha-1D & \quad \alpha-1L & \quad \alpha-2A & \quad \alpha-2B & \quad \alpha-2C & \quad \alpha-2D^* \\
\end{align*}
\]

\(\alpha-1A\) \quad Vascular Beds (vena cava, saphenous vein, pulmonary vein, mammary, mesenteric, splenic, hepatic, omental, renal, pulmonary, and epicardial coronary vessels)

\(\alpha-1B\) \quad Heart, CNS

\(\alpha-1D\) \quad Aorta

\(\alpha-1L\) \quad Vascular smooth muscle (19,20)

\(\alpha-2A\) \quad Presynaptic autoceptor in central neurons, CNS

\(\alpha-2B\) \quad Blood vessels

\(\alpha-2C\) \quad Adrenal medulla and brain

\(\alpha-2D^*\) \quad Bovine pineal gland and rat submaxillary gland

\(^*\)In animal models (9, 10)

**LOCATION OF ALPHA ADRENERGIC RECEPTORS**

<table>
<thead>
<tr>
<th>SUBTYPE ALPHA ADRENOCEPTOR</th>
<th>LOCATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>(\alpha-1A)</td>
<td>Vascular Beds (vena cava, saphenous vein, pulmonary vein, mammary, mesenteric, splenic, hepatic, omental, renal, pulmonary, and epicardial coronary vessels)</td>
</tr>
<tr>
<td>(\alpha-1B)</td>
<td>Heart, CNS</td>
</tr>
<tr>
<td>(\alpha-1D)</td>
<td>Aorta</td>
</tr>
<tr>
<td>(\alpha-1L)</td>
<td>Vascular smooth muscle (19,20)</td>
</tr>
<tr>
<td>(\alpha-2A)</td>
<td>Presynaptic autoceptor in central neurons, CNS</td>
</tr>
<tr>
<td>(\alpha-2B)</td>
<td>Blood vessels</td>
</tr>
<tr>
<td>(\alpha-2C)</td>
<td>Adrenal medulla and brain</td>
</tr>
<tr>
<td>(\alpha-2D^*)</td>
<td>Bovine pineal gland and rat submaxillary gland</td>
</tr>
</tbody>
</table>

\(\alpha\)-adrenoceptor
MECHANISM OF ALPHA ADRENERGIC RECEPTORS (12)

α-2 mediated mechanism:
- Inhibiting adenylyl cyclase(15)
- Attenuating cAMP response (16)
- Activating G-protein-gated potassium channels leading to membrane hyperpolarization(17)
- Inhibiting voltage gated calcium channels
- Activation of second messenger systems:
  a) Acceleration of Na⁺/H⁺ exchange
  b) Stimulation of phospholipase Cβ2 activity
  c) Stimulation of arachidonic acid mobilization
  d) increased phosphoinositide hydrolysis
  e) Increased intracellular availability of Calcium is involved in the smooth muscle-contracting effect of α2 adrenergic receptor agonists.
  f) Plays a major role in inhibiting Norepinephrine release from sympathetic nerve endings and suppressing sympathetic outflow from the brain

α-1 mediated mechanism:
- activation of the Gq-PLCβ-IP3-Ca²⁺ pathway (13)
- activation of other Ca²⁺ and calmodulin-sensitive pathways (14)
- activation of PKC. PKC phosphorylates many substrates, including membrane proteins such as channels, pumps, and ion-exchange proteins.
- stimulation of phospholipase A2 leads to the release of free arachidonate, which is then metabolized via the cyclooxygenase and lipoxygenase pathways to the bioactive prostaglandins and leukotrienes, respectively.
- Phospholipase D hydrolyzes phosphatidylcholine to yield phosphatic acid (PA).
- PA itself may act as a second messenger by releasing Ca²⁺ from intracellular stores, it also is metabolized to the second messenger DAG.
- Phospholipase D is an effector for ADP-ribosylating factor (ARF), suggesting that phospholipase D may play a role in membrane trafficking.
- α-1 receptors are capable of regulating a Ca²⁺ channel via a G protein.

FUNCTIONS OF ALPHA ADRENERGIC RECEPTORS

<table>
<thead>
<tr>
<th>SUBTYPE</th>
<th>FUNCTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>α₁A</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td>α₁B</td>
<td>Promotes cardiac growth, mediate behaviors such as reaction to novelty and exploration and are involved in behavioral sensitizations and in the vulnerability to addiction</td>
</tr>
<tr>
<td>α₁D</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td>α₁L</td>
<td>Vasoconstriction (19,20)</td>
</tr>
<tr>
<td>α₂A</td>
<td>Antinociceptive effects, sedation, hypothermia, hypotension, and behavioural actions.</td>
</tr>
<tr>
<td>α₂B</td>
<td>Vasoconstriction</td>
</tr>
<tr>
<td>α₂C</td>
<td>inhibiting the release of catecholamines from the adrenal medulla and modulating DA neurotransmission in the brain.</td>
</tr>
<tr>
<td>α₂D</td>
<td>Probable visual function in bovine neurosensory retina</td>
</tr>
</tbody>
</table>

*In animal models (9,10)

BRIEF REVIEW OF DRUGS AFFECTING α-ADRENERGIC RECEPTORS (18)

AGONISTS OF ALPHA ADRENERGIC RECEPTORS

- NON-SELECTIVE ENDODGENOUS CATECHOLAMINES
  1) Adrenaline
  2) Noradrenaline
  3) Dopamine

- NON-SELECTIVE SYNTHETIC CATECHOLAMINES
  1) Dipivefrine
  2) Dobutamine
  3) Fenoldopam
  4) Etilefrine
5) Talipexole (B-HT920)  
6) Octopamine  
7) Amitraz  
8) Indanidine  

**SELECTIVE α-1 AGONISTS (NON-CATECHOLAMINES)**  
1) Phenylephrine  
2) Methoxamine  
3) Naphazoline  
4) Oxymetazoline  
5) Xylometazoline  
6) Midodrine  
7) Mivazerol  
8) Cirazoline  

**SELECTIVE α-2 AGONISTS (NON-CATECHOLAMINES)**  
1) Clonidine  
2) Apraclonidine  
3) Brimonidine  
4) Alpha methyldopa  
5) Guanfacine  
6) Guanbenz  

**ANTAGONISTS OF ALPHA ADRENERGIC RECEPTORS**  
- **NON-SELECTIVE IRREVERSIBLE BLOCKERS**  
  1) Phenoxybenzamine  
- **NON-SELECTIVE REVERSIBLE BLOCKERS**  
  1) Phentolamine  
  2) Tolazoline  
  3) Anisodamine,  
- **SELECTIVE REVERSIBLE α-1 BLOCKERS**  
  1) Prazosin  
  2) Terazosin  
  3) Doxazosin  
  4) Alfuzosin  
  5) Bunazosin  
  6) Tamsulosin (α-1A subtype selective)  
  7) Silodosin  
  8) Indoramin  
  9) Urapidil  
- **SELECTIVE α-2 BLOCKERS**  
  1) Yohimbine  
  2) Idazoxan  
  3) Cirazoline  

II. Conclusion  
A major message of this review is that α 1, α 2, are the two major subtypes of α-adrenergic receptors, and that α 1- and α 2-adrenergic receptors are not more closely related to each other. The identification of multiple receptor subtypes for the major types of adrenergic receptors has obvious implications for drug therapy. It is to be expected that more and better selective drugs for the various subtypes will be developed in the near future. These will be important research tools as well as potentially new therapeutic agents. A major impediment at the current time to the development of better therapeutic agents is a paucity of knowledge as to which functions are mediated by which receptor subtypes. This is an area that clearly needs immediate attention. Current studies under way on the localization of the various subtypes in various tissues and regions of tissues may help to correlate receptor subtype with function. It appears that receptor subtype-specific antibodies may be developed in the near future and these will also be an important tool. Another important area in the next few
years will be a study of subtype-specific regulation of the protein and mRNA level. Further in the future it seems reasonable to expect that it may be possible to regulate levels of receptors and G proteins in order to produce therapeutic effects, rather than regulating the degree of receptor occupancy by the agonist as is currently done.

References

[2]. A STUDY OF THE ADRENOTROPIC RECEPTORS RAYMOND P. AHLQUIST, From the Department of Pharmacology, University of Georgia School of Medicine AUGUSTA, GEORGIA, June 1948, volume 153, pages 586-600
[11]. Subtypes of a1- and a2-adrenergic receptors -DAVID B. BYLUND Department of Pharmacology, College of Medicine, University of Nebraska Medical Center, Omaha, Neb 68198-6260, USA, Vol. 6 February 1992 The FASEB Journal, pages 832-839.